Glaxosmithkline LLC

Smithkline Beecham Corporation

Glaxo Group Limited

Smithkline Corporation

Joseph P Marino, Jr

Scott Kevin Thompson

Daniel F Veber

Barry A Morgan

Michael R Palovich

Yun Ding

Dennis Lee

James S Frazee

Hongxing Yan

Reema K Thalji

Krista B Goodman

Andrew Q Viet

Lara Kallander

Michael J Neeb

Mark A Hilfiker

Chun Ma

Haifeng Cui

Robert A Stavenger

Peng Li

Ning Wang

Allyn T Londregan

Zehong Wan

Dramane I Laine

Andrew W Viet

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.

sEH inhibitors and their use

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

Novel inhibitors of Rho-kinases are disclosed.

Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors

Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

1,2,4-triazole derivatives, compositions, process of making and methods of use

Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists 

Amide compounds and methods of using the same

Growing community of inventors

King of Prussia, PA, United States of America

Joseph P Marino, Jr